Enhanced anti-tumor and anti-angiogenic effects of metronomic cyclophosphamide combined with Endostar in a xenograft model of human lung cancer

Oncology Reports

Volumn 28, Issue 2, 2012, Pages 439-445

  Wang, Rui ^a   Qin, Shukui ^b   Chen, Yuqing ^a   Li, Yumei ^a   Chen, Changjie ^a   Wang, Zishu ^a   Zheng, Rongsheng ^a   Wu, Qiong ^a  

^a BENGBU MEDICAL COLLEGE   (China)

^b Nanjing Bayi Hospital   (China)

Author keywords

Angiogenesis; Cyclophosphamide; Endostar; Metronomic chemotherapy; Non small cell lung cancer

Indexed keywords

CYCLOPHOSPHAMIDE; RECOMBINANT ENDOSTATIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; LUNG CANCER; LUNG NON SMALL CELL CANCER; METRONOMIC DRUG ADMINISTRATION; MICROVASCULATURE; MOUSE; NONHUMAN; PERICYTE; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ADENOCARCINOMA; ADMINISTRATION, METRONOMIC; AMINO ACID SEQUENCE; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CYCLOPHOSPHAMIDE; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; ENDOSTATINS; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR SEQUENCE DATA; NEOVASCULARIZATION, PATHOLOGIC; RANDOM ALLOCATION; SURVIVAL ANALYSIS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84863445509     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1828     Document Type: Article

References (30)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005. (Pubitemid 40372904)
3. Goffin J, Lacchetti C, Ellis PM, Ung YC and Evans WK: First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review. J Thorac Oncol 5: 260-274, 2010.
4. Felip E, Cedrés S, Checa E and Martinez P: How to integrate current knowledge in selecting patients for first line in NSCLC? Ann Oncol 21 (Suppl 7): 230-233, 2010.
5. Thatcher N and Heighway J: Maintenance and consolidation therapy in patients with unresectable stage III/IV non-small cell lung cancer. Oncologist 15: 1034-1042, 2010.
6. Kerbel RS and Kamen BA: The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4: 423-436, 2004. (Pubitemid 38745528)
7. Pasquier E, Kavallaris M and Andre N: Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol 7: 455-465, 2010.
8. Man S, Bocci G, Francia G, Green SK, Jothy S, Hanahan D, Bohlen P, Hicklin DJ, Bergers G and Kerbel RS: Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res 62: 2731-2735, 2002. (Pubitemid 34525751)
9. Kong DS, Lee JI, Kim WS, Son MJ, Lim do H, Kim ST, Park K, Kim JH, Eoh W and Nam DH: A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomiderefractory glioblastoma. Oncol Rep 16: 1117-1121, 2006.
10. Song HF, Liu XW, Zhang HN, Zhu BZ, Yuan SJ, Liu SY and Tang ZM: Pharmacokinetics of His-tag recombinant human endostatin in Rhesus monkeys. Acta Pharmacol Sin 26: 124-128, 2005.
11. Jia H and Kling J: China offers alternative gateway for experimental drugs. Nat Biotechnol 24: 117-118, 2006. (Pubitemid 43221686)
12. Pietras K and Hanahan D: A multitargeted, metronomic, and maximum-tolerated dose 'chemo-switch' regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 23: 939-952, 2005. (Pubitemid 46202314)
13. Bertolini F, Paul S, Mancuso P, Monestiroli S, Gobbi A, Shaked Y and Kerbel RS: Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 63: 4342-4346, 2003. (Pubitemid 36951001)
14. Goon PK, Lip GY, Stonelake PS and Blann AD: Circulating endothelial cells and circulating progenitor cells in breast cancer: relationship to endothelial damage/dysfunction/apoptosis, clinicopathologic factors, and the Nottingham Prognostic Index. Neoplasia 11: 771-779, 2009.
15. Goon PK, Lip GY, Boos CJ, Stonelake PS and Blann AD: Circulating endothelial cells, endothelial progenitor cells, and endothelial microparticles in cancer. Neoplasia 8: 79-88, 2006.
16. Mancuso P, Calleri A, Cassi C, Gobbi A, Capillo M, Pruneri G, Martinelli G and Bertolini F: Circulating endothelial cells as a novel marker of angiogenesis. Adv Exp Med Biol 522: 83-97, 2003. (Pubitemid 36570529)
17. Folkman J: Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6: 273-286, 2007.
18. Raza A, Franklin MJ and Dudek AZ: Pericytes and vessel maturation during tumor angiogenesis and metastasis. Am J Hematol 85: 593-598, 2010.
19. Miyata Y, Kanda S, Ohba K, Nomata K, Hayashida Y, Eguchi J, Hayashi T and Kanetake H: Lymphangiogenesis and angiogenesis in bladder cancer: prognostic implications and regulation by vascular endothelial growth factors-A, -C, and -D. Clin Cancer Res 12: 800-806, 2006. (Pubitemid 43259860)
20. Mariucci S, Rovati B, Bencardino K, Manzoni M and Danova M: Flow cytometric detection of circulating endothelial cells and endothelial progenitor cells in healthy subjects. Int J Lab Hematol 32: E40-E48, 2008.
21. Martin-Padura I and Bertolini F: Circulating endothelial cells as biomarkers for angiogenesis in tumor progression. Front Biosci (Schol Ed) 1: 304-318, 2009.
22. Bertolini F, Shaked Y, Mancuso P and Kerbel RS: The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat Rev Cancer 6: 835-845, 2006. (Pubitemid 44629895)
23. Dellapasqua S, Bertolini F, Bagnardi V, Campagnoli E, Scarano E, Torrisi R, Shaked Y, Mancuso P, Goldhirsch A, Rocca A, Pietri E and Colleoni M: Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol 26: 4899-4905, 2008.
24. Furstenberger G, von Moos R, Lucas R, Thurlimann B, Senn HJ, Hamacher J and Boneberg EM: Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. Br J Cancer 94: 524-531, 2006. (Pubitemid 43289756)
25. Zhang H, Vakil V, Braunstein M, Smith EL, Maroney J, Chen L, Dai K, Berenson JR, Hussain MM, Klueppelberg U, Norin AJ, Akman HO, Ozçelik T and Batuman OA: Circulating endothelial progenitor cells in multiple myeloma: implications and significance. Blood 105: 3286-3294, 2005.
26. Laquente B, Vinals F and Germa JR: Metronomic chemotherapy: an antiangiogenic scheduling. Clin Transl Oncol 9: 93-98, 2007.
27. Ling Y, Yang Y, Lu N, You QD, Wang S, Gao Y, Chen Y and Guo QL: Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem Biophys Res Commun 361: 79-84, 2007. (Pubitemid 47102270)
28. Bocci G, Francia G, Man S, Lawler J and Kerbel RS: Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci USA 100: 12917-12922, 2003. (Pubitemid 37340000)
29. Murray A, Little SJ, Stanley P, Maraveyas A and Cawkwell L: Sorafenib enhances the in vitro anti-endothelial effects of low dose (metronomic) chemotherapy. Oncol Rep 24: 1049-1058, 2010.
30. Fidias P and Novello S: Strategies for prolonged therapy in patients with advanced non-small-cell lung cancer. J Clin Oncol 28: 5116-5123, 2010.